No 'Corrections And Removals' Reports For Device Enhancements, FDA Says
This article was originally published in The Gray Sheet
CDRH clarifies that 806 corrections and removals reports are not necessary for true product enhancements that do not qualify as recalls in a final guidance.
You may also be interested in...
The draft guidance is an attempt by FDA to reassure companies that they can make an enhancement to a marketed device without worrying that the action will be perceived as a recall. But the effort appears to have increased, rather than alleviated, industry anxieties.
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.